Literature DB >> 6174618

Characterization of a purified glycoprotein from Schistosoma mansoni eggs: specificity, stability, and the involvement of carbohydrate and peptide moieties in its serologic activity.

J Hamburger, S Lustigman, T K Siongok, J H Ouma, A A Mahmoud.   

Abstract

A major egg glycoprotein (MEG) was purified from a crude soluble extract of Schistosoma mansoni ova (Egyptian strain) by successive steps of lectin affinity and ion-exchange chromatography. Radioiodinated MEG exhibited a single precipitation band upon immunodiffusion against antiserum from chronically infected mice, and ran as a single band on PAGE (Rf 0.38) and SDS-PAGE (Rf 0.36). Its estimated m.w. was 70,000. The degree of stage and species specificity of MEG and the effect of various treatments on its serologic reactivity were determined by radioimmunoassay (RIA). A low degree of cross-reactivity between MEG and similarly prepared soluble antigens from adult worms and cercariae was demonstrated by RIA inhibition tests, whereas a high degree of cross-reactivity was found between MEG and a crude soluble S. haematobium egg antigen. In similar RIA inhibition tests, the Puerto Rican S. mansoni had a lower degree of cross-reactivity with S. haematobium than the Egyptian strain. MEG was four times more abundant in SEA from a Puerto Rican strain of S. mansoni than in SEA from the Egyptian strain. The serologic reactivity of MEG was stable to heat at 100 degrees C for 60 min, to 0.1 N NaOH or HCl, and to 10% TCA. Treatment of MEG with pronase caused a limited fragmentation of the molecule and some loss of its serologic reactivity. Periodate oxidation resulted in a substantial loss of molecular mass and of serologic reactivity, leaving a low residual activity that is only partially cross-reactive with the bulk of MEG. These results suggest the importance of both carbohydrate and peptide moieties of MEG for its serologic reactivity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174618

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Identification of 100 KDa protein in sera of mice-treated with Cu(II) complex with superoxide dismutase-mimetic activity.

Authors:  OmAli Y El-Khawaga; M M El-Naggar
Journal:  J Physiol Biochem       Date:  2003-03       Impact factor: 4.158

2.  43-kilodalton glycoprotein from Paracoccidioides brasiliensis: immunochemical reactions with sera from patients with paracoccidioidomycosis, histoplasmosis, or Jorge Lobo's disease.

Authors:  R Puccia; L R Travassos
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

3.  Immunoaffinity fractionation of Schistosoma mansoni worm antigens using human antibodies and its application for serodiagnosis.

Authors:  F N Boctor; H I Shaheen
Journal:  Immunology       Date:  1986-04       Impact factor: 7.397

4.  Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens.

Authors:  C Espitia; R Mancilla
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

5.  Utilization of fractionated soluble egg antigens reveals selectively modulated granulomatous and lymphokine responses during murine schistosomiasis mansoni.

Authors:  N W Lukacs; D L Boros
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

Review 6.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

7.  Splenic and granuloma T-lymphocyte responses to fractionated soluble egg antigens of Schistosoma mansoni-infected mice.

Authors:  N W Lukacs; D L Boros
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Identification of Schistosoma haematobium soluble egg antigens that elicit human granuloma formation in vitro.

Authors:  T Gaafar; S Ismail; M Helmy; A Afifi; N Guirguis; R el Ridi
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

9.  Schistosoma mansoni. Anti-egg monoclonal antibodies protect against cercarial challenge in vivo.

Authors:  D A Harn; M Mitsuyama; J R David
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.